Company profile for Seaport Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Seaport Therapeutics is a clinical-stage biopharmaceutical entity at the forefront of advancing novel neuropsychiatric medications to address significant unmet patient needs. Our approach involves leveraging our proprietary Glyph technology platform to overcome limitations previously hindering the progress of clinically validated mechanisms. Spearheaded by a seasoned team with a track record of involvement in inventing and dev...
Seaport Therapeutics is a clinical-stage biopharmaceutical entity at the forefront of advancing novel neuropsychiatric medications to address significant unmet patient needs. Our approach involves leveraging our proprietary Glyph technology platform to overcome limitations previously hindering the progress of clinically validated mechanisms. Spearheaded by a seasoned team with a track record of involvement in inventing and developing KarXT and other neuropsychiatric medicines, we are guided by an extensive network comprising renowned scientists, clinicians, and key opinion leaders.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Seaport Boston, MA 02210
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251104410929/en/Seaport-Therapeutics-to-Present-at-Stifel-2025-Healthcare-Conference

BUSINESSWIRE
04 Nov 2025

https://www.businesswire.com/news/home/20250918714981/en/Seaport-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences

BUSINESSWIRE
18 Sep 2025

https://www.businesswire.com/news/home/20250911263639/en/PureTech-Founded-Entity-Seaport-Therapeutics-Advances-Second-Therapeutic-Candidate-into-Clinical-Development-with-Dosing-of-First-Participant-in-Phase-1-Study-of-GlyphAgo-SPT-320-in-Healthy-Volunteers

BUSINESSWIRE
11 Sep 2025

https://www.businesswire.com/news/home/20250717210406/en/PureTech-Founded-Entity-Seaport-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2b-BUOY-1-Study-of-GlyphAllo-SPT-300-in-Major-Depressive-Disorder-MDD-With-or-Without-Anxious-Distress

BUSINESSWIRE
17 Jul 2025

https://www.businesswire.com/news/home/20250424996912/en/Seaport-Therapeutics-Presents-New-Preclinical-Data-on-SPT-320-Glyph-Agomelatine-at-the-Society-of-Biological-Psychiatry-SOBP-Annual-Meeting

BUSINESSWIRE
24 Apr 2025

https://www.businesswire.com/news/home/20250331018855/en/Seaport-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences-in-April

BUSINESSWIRE
31 Mar 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty